Focusing on the 87 cancer-associated mutations which affected 21/26 cases, all targeted genes previously found mutated in KMT2A-r leukemia, and typically PI3K/RAS-pathway genes and included KRAS (n = 27, 13 cases), NRAS (n = 19, 11 cases), FLT3 (n = 13, 8 cases), TP53 (n = 13, 8 cases), PIK3CA (n = 5, 4 cases), PAX5 (n = 5, 3 cases), PIK3R1 (n = 3, 2 cases), and PTPN11 (n = 2, 2 cases) (Figure 1D; Suppl. This evidence concerns the gene KRAS and cancer.